Description

Green Cross Holdings Corporation operates as a leading biotechnology enterprise with a diverse portfolio of pharmaceutical products. These include plasma derivatives, both prescription and over-the-counter medications, and specific treatments for Hunter syndrome. The company is also a key manufacturer of vaccines, covering diseases such as hemorrhagic fever, varicella, hepatitis-B, and influenza. Beyond its commercial offerings, Green Cross Holdings commits significant resources to the research and development of cutting-edge solutions in oncology, immunology, and cell therapy. It additionally supplies recombinant protein therapies for hemophilia. To foster the creation of new drugs and advanced technologies, the company engages in strategic partnerships and collaborations with other biotech firms and academic institutions. Established in 1967, Green Cross Holdings is headquartered in Yongin, South Korea.